Chu, MH

A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT‐NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 554-555

10.1002/hon.2632